We are live on ! Find out more
CNCR

ETF Series Solutions Trust Range Cancer Therapeutics ETF

Delisted

CNCR was delisted on the 27th of May, 2025.

10 hedge funds and large institutions have $2.89M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

15% more capital invested

Capital invested by funds: $2.52M → $2.89M (+$376K)

9% less funds holding

Funds holding: 1110 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
10
Holders Change
-1
Holders Change %
-9.09%
% of All Funds
0.27%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
3
Reduced
2
Closed
1
Calls
Puts
Net Calls
Net Calls Change

CNCR Hedge Fund Activity: Q3 2016 in Review

10 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q3 2016, worth a combined $2.89M — up 15% from $2.52M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CNCR and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.

The largest buyer was Susquehanna International Group, adding an estimated $386K. The largest seller was Jane Street, cutting an estimated $380K.

  • 10 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q3 2016, down from 11 in Q2 2016.
  • Funds reported $2.89M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q3 2016, up 15% quarter-over-quarter.
  • 0 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q3 2016 and 1 closed out, a net change of -1 holder.
  • The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q3 2016 was Susquehanna International Group, an estimated $386K added.
  • The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q3 2016 was Jane Street, an estimated $380K sold.

Based on aggregated 13F filings for Q3 2016.